T cells hold the power to transform the treatment of devastating human diseases

Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.


Integrating broad collaborations with the University of Pennsylvania (UPenn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity is developing personalized immunotherapies for cancer that are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.

February 9, 2021
Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration
January 25, 2021
Tmunity appoints Jeffrey Leiden M.D., Ph.D. as Chairman of the Board of Directors

Tmunity is the new center of gravity in translational T cell medicine, inventing the future of cell-based immunotherapy today.

Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body.

“Extraordinary advances have already been made with the development of the first generation of cell-based immunotherapies for cancer. We formed Tmunity, bringing together all the essential expertise, technology and scientific insight, to make the next great leap, to deliver the full promise of T cell medicine to patients.”

Carl H. June, MD